Inositec

Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions. Using its broadly applicable technology to adjust the chemical and physical properties of inositol phosphate (IP6) analogs, Inositec is developing a novel class of drugs currently focusing on high-unmet medical needs related to calcification disorders. The lead compound INS-3001 is a cardiovascular calcification inhibitor in development for aortic valve stenosis. Inositec was founded in December 2015 based on the award-winning research of Dr. Mattias Ivarsson, Prof. Jean-Christophe Leroux and Prof. Bastien Castagner at ETH Zurich, Switzerland.
Dr. Mattias Ivarsson about Verve Ventures
Verve Ventures has supported us in sharpening our value proposition and further widening our investor base with entrepreneurially-minded individuals that are keen to make impactful investment choices.
Founders / Management Dr. Mattias Ivarsson, Prof. Jean-Christophe Leroux, Prof. Bastien Castagner
Sectors Health & Bio, Pharma, Drug Discovery
Located in Switzerland
Co-Investors VI Partners
Follow On

LinkedIn

Sign up to receive our weekly newsletter and learn about investing in technologies that are changing the world.